



ImpediMed Limited

ABN 65 089 705 144

Unit 1
50 Parker Court
Pinkenba Qld 4008

Tel: +61 (0)7 3860 3700
Freecall: 1 800 638 477
Fax: +61 (0)7 3260 1225

Email:

ASX : IPD

29 April 2010

ASX ANNOUNCEMENT - APPENDIX 4C - QUARTER ENDED 31 March 2010

ImpediMed Limited is pleased to provide its Appendix 4C quarterly cash flow report (unaudited) for the quarter ended 31 March 2010.

Cash on hand as of 31 March 2010 was \$4.7 million.

Receipts from customers for the quarter were \$1.0 million.

Revenue for the current quarter was \$0.87 million, a decrease of 2% from the \$0.89 million of revenue for the previous quarter ended 31 December 2009 and an increase of 6% over the \$0.82 million for the quarter ended 31 March 2009.

The net cash use from operations for the quarter was (\$1.8 million), representing a reduction in cash use as compared to the (\$2.8 million) cash use for the previous quarter ended 31 December 2009, and (\$2.7 million) cash use for the quarter ended 31 March 2009.

ImpediMed continues to make significant progress in increasing the adoption by United States physicians and healthcare payers of L-Dex® technology in aiding in the assessment of lymphoedema, as evidenced by the Company's recent milestones.

- The approval by the American Medical Association in March 2010 of a unique Category III CPT code specifically for Bioimpedance Spectroscopy measurement of fluid differences between the limbs.
- The appointment of Walton A. Taylor, M.D. as ImpediMed's first Medical Director
- FDA application filed in March 2010 to expand the use of ImpediMed's L-Dex® device for use in aiding in the assessment of unilateral lymphoedema in legs.
- Increase to 82 L-Dex® devices in use in the US as of 31 March 2010.

For personal use only

For personal use only

ImpediMed remains committed to advancing research & development, as well as commercialisation programs, needed to succeed in its primary lymphoedema markets in the United States. To fund the Company's continued progress, the Company announced on 1 April 2010 an institutional placement and non-renounceable pro rata entitlement offer to raise up to \$20.1 million. On 9 April 2010, the Company completed the \$10 million institutional placement. The entitlement offer is scheduled to close on 7 May 2010.

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001, 24/10/2005.

Name of entity

ImpediMed Limited

ABN

65 089 705 144

Quarter ended ("current quarter")

31st March 2010

Consolidated statement of cash flows

Cash flows related to operating activities	3rd Quarter 2010 \$'000	Year to date (9 months) \$'000
1.1 Receipts from customers	1,007	2,801
1.2 Receipts from grants	0	0
1.3 Payments to suppliers and employees	(2,881)	(11,249)
1.4 Interest received	38	109
1.5 Interest paid	(1)	(1)
1.6 R&D tax offset received	0	0
1.7 Other (provide details if material)	0	0
Net operating cash flows	(1,837)	(8,340)

+ See chapter 19 for defined terms.

For personal use only

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

	3rd Quarter 2010 \$'000	Year to date (9 months) \$'000
1.8 Net operating cash flows (carried forward)	(1,837)	(8,340)
Cash flows related to investing activities		
1.9 Payment for acquisition of:		
(a) businesses (item 5)	0	0
(b) equity investments	0	0
(c) intellectual property	0	0
(d) physical non-current assets	(17)	(48)
(e) other non-current assets	0	(2)
1.10 Proceeds from disposal of:		
(a) businesses (item 5)	0	0
(b) equity investments	0	0
(c) intellectual property	0	0
(d) physical non-current assets	0	0
(e) other non-current assets	0	0
1.11 Loans to other entities	0	0
1.12 Loans repaid by other entities	0	0
1.13 Other (provide details if material)	0	0
Net investing cash flows	(17)	(50)
1.14 Total operating and investing cash flows	(1,854)	(8,390)
Cash flows related to financing activities		
1.15 Proceeds from issues of shares, options, etc.	0	6,972
1.16 Costs from capital raise	0	(368)
1.17 Proceeds from borrowings	0	0
1.18 Repayment of borrowings	0	0
1.19 Dividends paid	0	0
1.20 Other (provide details if material)	0	0
Net financing cash flows	0	6,604
Net increase (decrease) in cash held	(1,854)	(1,786)
1.21 Cash at beginning of quarter/year to date	6,669	6,634
1.22 Exchange rate adjustments to items 1.12, 1.20	(103)	(136)
1.23 Cash at end of quarter	4,712	4,712

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		3rd Quarter 2010 \$'000
1.24	Aggregate amount of payments to the parties included in item 1.3	189
1.25	Aggregate amount of loans to the parties included in item 1.11	N/A

1.26 Explanation necessary for an understanding of the transactions

Payments to directors consist of Directors' salaries and the Directors' fees for the quarter, including superannuation. This excludes any amounts that were unpaid as at the end of the quarter.

Non-cash financing and investing activities

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

		Amount available \$'000	Amount used \$'000
3.1	Loan facilities	—	—
3.2	Credit standby arrangements	—	—

+ See chapter 19 for defined terms.

For personal use only

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	3rd Quarter 2010 \$'000	2nd Quarter 2010 \$'000
4.1 Cash on hand and at bank	4,712	6,669
4.2 Deposits at call	0	0
4.3 Bank overdraft	0	0
4.4 Other (provide details)	0	0
Total: cash at end of quarter (item 1.23)	4,712	6,669

Acquisitions and disposals of business entities

	Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1 Name of entity	N/A	N/A
5.2 Place of incorporation or registration	N/A	N/A
5.3 Consideration for acquisition or disposal	N/A	N/A
5.4 Total net assets	N/A	N/A
5.5 Nature of business	N/A	N/A

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.



Sign here:

Date: 29th April 2009

Print name: Donald Myll,
Chief Financial Officer

+ See chapter 19 for defined terms.

For personal use only

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, *AASB 1026: Statement of Cash Flows* apply to this report except for the paragraphs of the Standard set out below.
 - 6.2 - reconciliation of cash flows arising from operating activities to operating profit or loss
 - 9.2 - itemised disclosure relating to acquisitions
 - 9.4 - itemised disclosure relating to disposals
 - 12.1(a) - policy for classification of cash items
 - 12.3 - disclosure of restrictions on use of cash
 - 13.1 - comparative information
3. **Accounting Standards.** ASX will accept, for example, the use of International Accounting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

+ See chapter 19 for defined terms.